Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism

@article{Mercier2010LetterTT,
  title={Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism},
  author={C{\'e}dric Mercier and Laetitia Dahan and L’houcine Ouafik and Nicolas Andr{\'e} and Joseph Ciccolini},
  journal={European Journal of Clinical Pharmacology},
  year={2010},
  volume={66},
  pages={959-960}
}
Dear Sir, We have read with great interest the article entitled “Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism” by J. Maring et al. which was recently published in the European Journal of Clinical Pharmacology [1]. We would like to comment on the article by referring to our own… CONTINUE READING